Recent studies showed that WT1 is activated in pancreatic cancer and that patients with elevated BASP1 levels have a significantly better prognosis than individuals whose cancer cells contain no BASP1 but high WT1 levels (Zhou et al., 2019). This evidence concerns the gene BASP1 and pancreatic neoplasm.